Advanced search
Publication Cover
Leukemia & Lymphoma Volume 50, 2009 - Issue 9
Submit an article Journal homepage
896
Views
26
CrossRef citations to date
0
Altmetric
Original Articles: Research

Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98)

R. Zenhäusern Department of Medical Oncology, Inselspital Bern, SwitzerlandCorrespondence[email protected]
, MD,
S.-F. Hsu Schmitz SAKK Coordinating Center, Bern, Switzerland
,
M. Solenthaler Division of Hematology, Inselspital Bern, Switzerland
,
D. Heim Division of Hematology, Kantonsspital Basel, Switzerland
,
S. Meyer-Monard Division of Hematology, Kantonsspital Basel, Switzerland
,
U. Hess Division of Oncology/Hematology, Kantonsspital St. Gallen, Switzerland
,
L. Leoncini Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
,
M. Bargetzi Center of Oncology/Hematology and Transfusion Medicine, Kantonsspital Aarau, Switzerland
,
B. Rufener SAKK Coordinating Center, Bern, Switzerland
&
A. Tobler Division of Hematology, Inselspital Bern, Switzerland
 show all
Pages 1501-1511 | Received 08 Mar 2009, Accepted 19 Jun 2009, Published online: 15 Sep 2009

References

  • Pettitt A R, Zuzel M, Cawley J C. Hairy-cell leukaemia: Biology and management. Br J Haematol 1999; 106: 2–8
  • Tallman M S, Peterson L C, Hakimian D, et al. Treatment of hairy-cell leukemia: current views. Semin Hematol 1999; 36: 155–163
  • Ahmed S, Rai K R. Interferon in the treatment of hairy-cell leukemia. Best Pract Res Clin Haemtol 2003; 16: 69–81
  • Mey U, Strehl J, Gorschlüter M, et al. Advances in the treatment of hairy-cell leukaemia. Lancet Oncol 2003; 4: 86–94
  • Grever M, Kopecky K, Foucar M K, et al. Randomized comparison of pentostatin versus interferon α- 2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 1995; 13: 974–982
  • Piro L D, Carrera C J, Carson D A, et al. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990; 322: 1117–1121
  • Tallman M S, Hakimian D, Variakojis D, et al. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 1992; 80: 2203–2209
  • Hoffman M A, Janson D, Rose E, et al. Treatment of hairy-cell leukemia with cladribine: Response, toxicity, and long-term follow-up. J Clin Oncol 1997; 15: 1138–1142
  • Cheson B D, Sorensen J M, Vena D A, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 1998; 16: 3007–3015
  • Tallman M S, Hakimian D, Rademaker A W, et al. Relapse of hairy cell leukaemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience. Blood 1996; 88: 1954–1959
  • Saven A, Burian C, Koziol A, et al. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998; 92: 1918–1926
  • Goodman G R, Burian C, Koziol J A, et al. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003; 21: 891–896
  • Juliusson G, Heldal D, Hippe E, et al. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol 1995; 13: 989–995
  • Liliemark J, Albertioni F, Hassan M, et al. On the bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine in humans: alternative routes of administration. J Clin Oncol 1992; 10: 1514–1518
  • Sonderegger T, Betticher D C, Cerny T, et al. Pharmacokonetics of 2-chloro-2′-deoxyadenosine administered subcutaneously or by continuous intravenous infusion. Cancer Chemother Pharmacol 2000; 46: 40–42
  • Von Rohr A, Schmitz S F, Tichelli A, et al. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study. Ann Oncol 2002; 13: 1641–1649
  • Lauria F, Bocchia M, Marotta G, et al. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications. Haematologica 1999; 84: 22–25
  • Chacko J, Murphy C, Duggan C, et al. Weekly intermittent 2-CDA is less toxic and equally efficacious when compared to continous infusion in hairy cell leukemia. Br J Haematol 1999; 105: 1145–1146
  • Anonymous. Consensus resolution: proposed criteria for evaluation of response to treatment in hairy cell leukaemia. Leukemia 1987; 1: 405
  • Frison L, Pocock S. Repeated measures in clinical trials: analysis using mean summary statsistics and its implications for design. Stat Med 1992; 11: 1685–1704
  • Zinzani P L, Tani M, Marchi E, et al. Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Haematologica 2004; 89: 309–313
  • Robak T, Jamroziak K, Gora-Tybor J, et al. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukaemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood 2007; 109: 3672–3675
  • Zenhäusern R, Von Rohr A, Rufibach K, et al. Low dose 2-chlorodeoxyadenosine given as a single subcutaneous injection in patients with hairy cell leukemia: a multicentre trial SAKK 32/95. Leuk Lymphoma 2009; 50: 133–136
  • Ginaldi L, De Martinis M, Matutes E, et al. Levels of expression of CD19 and CD20 in chronic B cell leukemias. J Clin Pathol 1998; 51: 364–369
  • Thomas D A, O'Brien S, Bueso-Ramos C, et al. Rituximab in relapsed or refractory hairy cell leukaemia. Blood 2003; 102: 3906–3911

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.